OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial
Monika Kellerer, Margit S. Kaltoft, Jack Lawson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 9, pp. 1788-1799
Open Access | Times Cited: 39
Monika Kellerer, Margit S. Kaltoft, Jack Lawson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 9, pp. 1788-1799
Open Access | Times Cited: 39
Showing 1-25 of 39 citing articles:
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 30
Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1206-1222
Open Access | Times Cited: 30
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 37
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 37
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 36
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1658-1667
Open Access | Times Cited: 25
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
Cătălin Vlăduț Ionuț Feier, Razvan Constantin Vonica, Alaviana Monique Faur, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4346-4346
Open Access | Times Cited: 15
Cătălin Vlăduț Ionuț Feier, Razvan Constantin Vonica, Alaviana Monique Faur, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4346-4346
Open Access | Times Cited: 15
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1297-1314
Open Access | Times Cited: 11
Shahad Sabaawi Ibrahim, Raghad Sabaawi Ibrahim, Batoul Arabi, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1297-1314
Open Access | Times Cited: 11
Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials
Sharath Kommu, Richard L. Berg
Obesity Reviews (2024) Vol. 25, Iss. 9
Open Access | Times Cited: 6
Sharath Kommu, Richard L. Berg
Obesity Reviews (2024) Vol. 25, Iss. 9
Open Access | Times Cited: 6
Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery
Jean‐Baptiste Bonnet, Sarah Tournayre, Jean Anitcheou, et al.
Obesity (2023) Vol. 32, Iss. 1, pp. 50-58
Open Access | Times Cited: 15
Jean‐Baptiste Bonnet, Sarah Tournayre, Jean Anitcheou, et al.
Obesity (2023) Vol. 32, Iss. 1, pp. 50-58
Open Access | Times Cited: 15
The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis
Wei Wu, Huo-mu Tong, Yunsheng Li, et al.
Endocrine (2023) Vol. 83, Iss. 3, pp. 571-584
Open Access | Times Cited: 13
Wei Wu, Huo-mu Tong, Yunsheng Li, et al.
Endocrine (2023) Vol. 83, Iss. 3, pp. 571-584
Open Access | Times Cited: 13
Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
Enda Murphy, Francis Finucane
International Journal of Obesity (2024)
Open Access | Times Cited: 5
Enda Murphy, Francis Finucane
International Journal of Obesity (2024)
Open Access | Times Cited: 5
Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis
Yanan Ding, Yufei Shi, Ruifang Guan, et al.
Pharmacological Research (2023) Vol. 199, pp. 107031-107031
Open Access | Times Cited: 12
Yanan Ding, Yufei Shi, Ruifang Guan, et al.
Pharmacological Research (2023) Vol. 199, pp. 107031-107031
Open Access | Times Cited: 12
Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose–High-Lipid Conditions: A Comparative Study
Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 421-421
Open Access
Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 421-421
Open Access
Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
Mohsina Patwekar, Faheem Patwekar, J. Pavan Kumar, et al.
BIO Integration (2025) Vol. 6, Iss. 1
Open Access
Mohsina Patwekar, Faheem Patwekar, J. Pavan Kumar, et al.
BIO Integration (2025) Vol. 6, Iss. 1
Open Access
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?
Abdelilah Arredouani
Pharmacology & Therapeutics (2025), pp. 108824-108824
Closed Access
Abdelilah Arredouani
Pharmacology & Therapeutics (2025), pp. 108824-108824
Closed Access
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Svea Stüdemann, Stefan Engeli
Adipositas - Ursachen Folgeerkrankungen Therapie (2025) Vol. 19, Iss. 01, pp. 39-57
Closed Access
Svea Stüdemann, Stefan Engeli
Adipositas - Ursachen Folgeerkrankungen Therapie (2025) Vol. 19, Iss. 01, pp. 39-57
Closed Access
Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, et al.
Diabetes Research and Clinical Practice (2025), pp. 112086-112086
Closed Access
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, et al.
Diabetes Research and Clinical Practice (2025), pp. 112086-112086
Closed Access
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists
Qi Wu, Yan Zeng, Yong Liu, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Qi Wu, Yan Zeng, Yong Liu, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
JAMES AMAMOO, Riddhi Doshi, Joshua Noone, et al.
Diabetes Therapy (2025)
Open Access
JAMES AMAMOO, Riddhi Doshi, Joshua Noone, et al.
Diabetes Therapy (2025)
Open Access
Long‐Term Effectiveness of Once‐Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real‐World Study
Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 4
Open Access
Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 4
Open Access
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Yiwen Liu, Liyun He, S. S. Han, et al.
Journal of the American Heart Association (2025)
Open Access
Yiwen Liu, Liyun He, S. S. Han, et al.
Journal of the American Heart Association (2025)
Open Access
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Francesco Natale, Ettore Luisi, Rosa Franzese, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 5, pp. 145-145
Open Access | Times Cited: 3
Francesco Natale, Ettore Luisi, Rosa Franzese, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 5, pp. 145-145
Open Access | Times Cited: 3
Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials
Sijin Wu, Wenzhao Lu, Zhongli Chen, et al.
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Sijin Wu, Wenzhao Lu, Zhongli Chen, et al.
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 15
